ScripBristol Myers Squibb is three years away from facing generic and biosimilar competitors for its two top-selling products – Eliquis (apixaban) and Opdivo (nivolumab), which delivered 52% of the company
Pink SheetHospital systems Bon Secours Mercy Health and the Cleveland Clinic told Senate investigators that they do not pass 340B drug discounts directly to patients because Congress did not design the 340B pro
Pink SheetSigns the Trump Administration will shift regulatory oversight of the 340B outpatient drug discount to the US Centers for Medicare and Medicaid Services may be good news for manufacturers. The Trump A
ScripWith biopharma investors eager for hard numbers on the impact of the Trump administration’s tariff policy on corporate financials, Merck & Co. CEO Robert Davis offered some answers on 24 April, sa
Pink SheetThe heads of two of Europe’s largest pharma companies urged the EU to increase drug prices to be more in line with the US, a move unlikely to be greeted enthusiastically in the cash-strapped continent
ScripThe heads of two of Europe’s pharma powerhouses have urged the EU to increase drug prices towards levels paid in the US, a move which is unlikely to be greeted with enthusiasm on the cash-strapped con
ScripRegeneron Pharmaceuticals is the latest biopharma company to announce an investment in its manufacturing and research and development footprint in the US. But while similar moves by other firms have b
ScripGalapagos revealed its second leadership transition in as many weeks on 22 April, reporting that CEO Paul Stoffels plans to retire from the company upon the appointment of a new chief executive, who w